Evidence map›Paper›PMID 20339825›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2010

Betulinic acid a radiosensitizer in head and neck squamous cell carcinoma cell lines.

Christina Eder-Czembirek, Boban M Erovic, Cornelia Czembirek, Markus Brunner, Edgar Selzer, Richard Pötter, Dietmar Thurnher

Abstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Effect of the coffee ingredient cafestol on head and neck squamous cell carcinoma cell lines.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2015
    Article
  8. Article
  9. Article
  10. Article
  11. The effect of resveratrol in combination with irradiation and chemotherapy: study using Merkel cell carcinoma cell lines.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2014
    Article
  12. Article
  13. Article
  14. The combination of hyperthermia or chemotherapy with gimeracil for effective radiosensitization.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2012
    Article
  15. High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2012
    Article
  16. Cisplatin superior to carboplatin in adjuvant radiochemotherapy for locally advanced cancers of the oropharynx and oral cavity.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2012
    Article
  17. Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN).Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2011
    Article
  18. Article
  19. Combined-modality treatment in advanced oral squamous cell carcinoma: Primary surgery followed by adjuvant concomitant radiochemotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2011
    Article
  20. Radiosensitization of head and neck cancer cells by the phytochemical agent sulforaphane.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Christina Eder-CzembirekDepartment of Cranio-, Maxillofacial and Oral Surgery, Medical University of Vienna, Währinger Gürtel 18–20, Vienna, Austria.
Boban M Erovic
Cornelia Czembirek
Markus Brunner
Edgar Selzer
Richard Pötter
Dietmar Thurnher
Medical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeBetulinic acid, a pentacyclic triterpene, is a new cytotoxic compound active on melanoma, neuroblastoma, glioblastoma and head and neck squamous cell carcinoma (HNSCC) cells. In combination with irradiation it has been shown to have an additive effect on growth inhibition in melanoma cells. In this study, the radiosensitizing effect of betulinic acid on sequential irradiation was investigated in HNSCC cell lines. MATERIAL AND

methodsTwo HNSCC cell lines, SCC9 and SCC25, were treated with increasing doses of betulinic acid and sequentially irradiated with a single boost of 4 Gy from a conventional radiation source. The cells were counted, the surviving fraction was determined, and colony-forming assays were performed.

resultsIt could be shown that betulinic acid alone inhibits cell survival, affects cell survival additively in combination with irradiation and decreases clonogenic survival in both cell lines when applied alone.

conclusionBetulinic acid could be a promising treatment agent in radioresistant head and neck cancer. A combination of betulinic acid with radiotherapy seems to be beneficial.

Indexed as

Betulinic AcidCarcinoma, Squamous CellCell LineCell SurvivalDose-Response Relationship, DrugHead and Neck NeoplasmsHumansPentacyclic TriterpenesRadiation-Sensitizing AgentsRadiotherapy DosageTreatment OutcomeTriterpenesBetulinic AcidPentacyclic TriterpenesRadiation-Sensitizing AgentsTriterpenes

Identifiers

PMID20339825
OpenAlexW1595818660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.